publication venue for
- Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.. 34. 2008
- KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. 2020
- Osteosarcoma treatment - where do we stand? A state of the art review. 2013
- Neuroblastoma: Therapeutic strategies for a clinical enigma. 2010
- Advanced gastric cancer--slow but steady progress. 2010
- Esophagogastric cancer: targeted agents. 2010
- Advances in neoadjuvant therapy for colorectal cancer with liver metastases. 2008
- De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice. 2026
- The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer. 2024
- Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going. 2024
- Rethinking breast cancer follow-up based on individual risk and recurrence management. 2022
- Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. 2022
- Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations. 2021
- Turning tumors from cold to inflamed to improve immunotherapy response. 2021
- Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. 2017
- Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. 2017
- Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. 2017
- Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. 2017
- Clinical trial designs incorporating predictive biomarkers. 2016
- Clinical characteristics of patients with relapsed multiple myeloma. 2015
- Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. 2012